The round, in addition to the $85m previously announced in April 2019, was led by HealthQuest Capital with participation from Aisling Capital and Polaris Partners.
Ajax Health seeks to identify, invest in and scale disruptive technologies in the medical device space. Taking an active operating role, the Ajax team has a proven track record of helping companies of all sizes, stages and structures achieve their value-creation goals.
A portion of the capital has already been deployed for investments in Ablacon Inc. and Cortica Inc.
Ablacon is a Wheat Ridge, CO-based company developing an advanced mapping system to guide the treatment of atrial fibrillation (AFib), one of the most common cardiac arrythmias. The company’s system uses machine learning to precisely localize and characterize the sources of AFib and to guide targeted therapy by visualizing the Electrographic Flow within the cardiac chambers. Ablacon’s technology obtained a CE Mark in 2018 and is currently being used in Europe.
San Diego based Cortica is a provider of advanced neurological therapies for children with autism and other neurodevelopmental conditions. The company offers a comprehensive set of services through its integrated care model that incorporates therapies from neurophysiology, biochemistry, sensorimotor integration, communication, cognition and behavior. Cortica delivers its services in-clinic, in-home and via telehealth to empower families to achieve long-lasting, transformative results. It operates clinics throughout California serving global patients seeking a more advanced treatment for autism.
The remainder of the money raised will be used to strategically operate and expand additional, innovative medical device companies.